BioNexus Gene Lab (BGLC) Long-Term Deferred Tax (2021 - 2026)

BioNexus Gene Lab (BGLC) posted Long-Term Deferred Tax of $12.2 million for Q1 2026, up 29.33% sequentially from $9.4 million in Q4 2024.

BioNexus Gene Lab (BGLC) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends

BioNexus Gene Lab has reported Long-Term Deferred Tax for 3 years, with the latest figure at $12.2 million in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (changed N/A YoY) and the FY2024 annual result came in at $9.4 million, changed N/A from the prior year.
Long-Term Deferred Tax advanced to $12.2 million in Q1 2026 per BGLC's latest filing, from $9.4 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $12.2 million in Q1 2026 and troughed at $9.4 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Linde	225.67 Bn	220.77 Bn	4.43 Bn
2	Sherwin Williams	84.74 Bn	84.44 Bn	3.34 Bn
3	Ecolab	78.90 Bn	73.77 Bn	1.95 Bn
4	Air Products & Chemicals	68.19 Bn	67.21 Bn	1.04 Bn
5	Ppg Industries	25.36 Bn	23.77 Bn	1.81 Bn
6	Chemical & Mining Co Of Chile	23.48 Bn	19.61 Bn	778.60 Mn
7	LyondellBasell Industries	21.91 Bn	19.28 Bn	2.04 Bn
8	International Flavors & Fragrances	21.51 Bn	20.94 Bn	853.00 Mn
9	DuPont de Nemours	18.83 Bn	17.09 Bn	639.00 Mn
10	BioNexus Gene Lab	2.28 Mn	-1.25 Mn	12,982.00

Download Data